Artículos de revistas sobre el tema "CDKIs"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "CDKIs".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Campbell, Grace Jean, Emma Langdale Hands y Mathew Van de Pette. "The Role of CDKs and CDKIs in Murine Development". International Journal of Molecular Sciences 21, n.º 15 (28 de julio de 2020): 5343. http://dx.doi.org/10.3390/ijms21155343.
Texto completoGiannone, Gaia, Valentina Tuninetti, Eleonora Ghisoni, Sofia Genta, Giulia Scotto, Gloria Mittica y Giorgio Valabrega. "Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer". International Journal of Molecular Sciences 20, n.º 9 (12 de mayo de 2019): 2353. http://dx.doi.org/10.3390/ijms20092353.
Texto completoPhuong, Lisa, Janki Patel, Nadia Baka, Jessica Goldman, Michael Lyudmer, Stephanie Shamir, Junwen Deng, Alvaro Alvarez Soto y Jesus Del Santo Anampa Mesias. "Effect of cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) on body composition (BC) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC)." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): e13033-e13033. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13033.
Texto completoChao, Sheng-Hao, John R. Walker, Sumit K. Chanda, Nathanael S. Gray y Jeremy S. Caldwell. "Identification of Homeodomain Proteins, PBX1 and PREP1, Involved in the Transcription of Murine Leukemia Virus". Molecular and Cellular Biology 23, n.º 3 (1 de febrero de 2003): 831–41. http://dx.doi.org/10.1128/mcb.23.3.831-841.2003.
Texto completoDao, Mo A. y Catherine M. Verfaillie. "STI571 Suppresses Proliferation by Restoring Nuclear Cyclin Dependent Kinase Inhibitors (CDKIs) while STI571+TRAIL Promotes Cell Death by Decreasing Cytoplasmic CDKIs." Blood 104, n.º 11 (16 de noviembre de 2004): 1992. http://dx.doi.org/10.1182/blood.v104.11.1992.1992.
Texto completoAbdelmalak, Mary, Rajanbir Singh, Mohammed Anwer, Pavel Ivanchenko, Amritdeep Randhawa, Myra Ahmed, Anthony W. Ashton, Yanming Du, Xuanmao Jiao y Richard Pestell. "The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance". Cancers 14, n.º 21 (1 de noviembre de 2022): 5388. http://dx.doi.org/10.3390/cancers14215388.
Texto completoGervaso, Lorenzo, Alberto J. Montero, Xuefei Jia y Alok A. Khorana. "Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e18184-e18184. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18184.
Texto completoZeki, K., I. Morimoto, T. Arao, S. Eto y U. Yamashita. "Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA". Journal of Endocrinology 160, n.º 1 (1 de enero de 1999): 67–73. http://dx.doi.org/10.1677/joe.0.1600067.
Texto completoBuckley, S., B. Driscoll, K. D. Anderson y D. Warburton. "Cell cycle in alveolar epithelial type II cells: integration of Matrigel and KGF". American Journal of Physiology-Lung Cellular and Molecular Physiology 273, n.º 3 (1 de septiembre de 1997): L572—L580. http://dx.doi.org/10.1152/ajplung.1997.273.3.l572.
Texto completoBencivenga, Debora, Emanuela Stampone, Angela Vastante, Myassar Barahmeh, Fulvio Della Ragione y Adriana Borriello. "An Unanticipated Modulation of Cyclin-Dependent Kinase Inhibitors: The Role of Long Non-Coding RNAs". Cells 11, n.º 8 (14 de abril de 2022): 1346. http://dx.doi.org/10.3390/cells11081346.
Texto completoMason, Jeremy, Yutao Gong, Laleh Amiri-Kordestani, Suparna Wedam, Jennifer J. Gao, Tatiana M. Prowell, Harpreet Singh et al. "Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer". JCO Clinical Cancer Informatics, n.º 5 (junio de 2021): 758–67. http://dx.doi.org/10.1200/cci.21.00025.
Texto completoMatushansky, Igor, Farshid Radparvar y Arthur I. Skoultchi. "Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors". Blood 96, n.º 8 (15 de octubre de 2000): 2755–64. http://dx.doi.org/10.1182/blood.v96.8.2755.
Texto completoMatushansky, Igor, Farshid Radparvar y Arthur I. Skoultchi. "Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors". Blood 96, n.º 8 (15 de octubre de 2000): 2755–64. http://dx.doi.org/10.1182/blood.v96.8.2755.h8002755_2755_2764.
Texto completoSchwartz, Gary K. y Manish A. Shah. "Targeting the Cell Cycle: A New Approach to Cancer Therapy". Journal of Clinical Oncology 23, n.º 36 (20 de diciembre de 2005): 9408–21. http://dx.doi.org/10.1200/jco.2005.01.5594.
Texto completoDeSouza, Karen, Daniel Yeo, Maria Diossy, Sumbal Umar, Emma Gore, Sachin Trivedi, Anjana Anand, Srinivasan Madhusudan y Sarah Khan. "Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC)." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): e13031-e13031. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13031.
Texto completoRichter, Anna, Nina Schoenwaelder, Sina Sender, Christian Junghanss y Claudia Maletzki. "Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches". Cancers 13, n.º 10 (20 de mayo de 2021): 2497. http://dx.doi.org/10.3390/cancers13102497.
Texto completoGao, Jennifer J., Joyce Cheng, Tatiana Michelle Prowell, Erik Bloomquist, Shenghui Tang, Suparna B. Wedam, Melanie E. Royce et al. "Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 1055. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1055.
Texto completoCroucher, David R., Danny Rickwood, Carole M. Tactacan, Elizabeth A. Musgrove y Roger J. Daly. "Cortactin Modulates RhoA Activation and Expression of Cip/Kip Cyclin-Dependent Kinase Inhibitors To Promote Cell Cycle Progression in 11q13-Amplified Head and Neck Squamous Cell Carcinoma Cells". Molecular and Cellular Biology 30, n.º 21 (30 de agosto de 2010): 5057–70. http://dx.doi.org/10.1128/mcb.00249-10.
Texto completoKhosravi, Mohammad Reza, Mohammad Hossein Mohammadi, Parinaz Khadem, Sahar Lashkari, Hamideh Aghaeenezhad, Ahmad Gharehbaghian, Zaher Khazaei y Mehdi Allahbakhshian Farsani. "Evaluation of P21Cip1 and P27Kip1 expression in de novo acute lymphoblastic leukemia patients". Biomedical Research and Therapy 5, n.º 7 (28 de julio de 2018): 2518–27. http://dx.doi.org/10.15419/bmrat.v5i7.461.
Texto completoRoncato, Rossana, Jacopo Angelini, Arianna Pani, Erika Cecchin, Andrea Sartore-Bianchi, Salvatore Siena, Elena De Mattia, Francesco Scaglione y Giuseppe Toffoli. "CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions". International Journal of Molecular Sciences 21, n.º 17 (1 de septiembre de 2020): 6350. http://dx.doi.org/10.3390/ijms21176350.
Texto completoAdona, Paulo Roberto y Cláudia Lima Verde Leal. "Meiotic inhibition with different cyclin-dependent kinase inhibitors in bovine oocytes and its effects on maturation and embryo development". Zygote 12, n.º 3 (agosto de 2004): 197–204. http://dx.doi.org/10.1017/s0967199404002771.
Texto completoRiess, Christin, Katharina del Moral, Adina Fiebig, Philipp Kaps, Charlotte Linke, Burkhard Hinz, Anne Rupprecht et al. "HGG-13. Combined CDK inhibition and arginine-deprivation as targeted therapy for arginine-auxotrophic glioblastoma multiforme cells". Neuro-Oncology 24, Supplement_1 (1 de junio de 2022): i62—i63. http://dx.doi.org/10.1093/neuonc/noac079.228.
Texto completoMou, Jiajia, Danghui Chen y Yanru Deng. "Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment". Medicinal Chemistry 16, n.º 3 (17 de abril de 2020): 307–25. http://dx.doi.org/10.2174/1573406415666190626113900.
Texto completoJerez, Jose Manuel, Nuria Ribelles, Pablo Rodriguez-Brazzarola, Tamara Diaz Redondo, Begoña Jimenez Rodriguez, Alfonso Sanchez-Muñoz, Antonia Marquez et al. "Prediction of early progression (EP) to CDKIs first line treatment in ER+/HER2- metastatic breast cancer (MBC) using machine learning." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e13040-e13040. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e13040.
Texto completoHan, Xu, Yijin Kuang, Huiyong Chen, Ting Liu, Ji Zhang y Jing Liu. "p19INK4d: More than Just a Cyclin-Dependent Kinase Inhibitor". Current Drug Targets 21, n.º 1 (20 de diciembre de 2019): 96–102. http://dx.doi.org/10.2174/1389450120666190809161901.
Texto completoBryant, Patrick, Qingxia Zheng y Kevin Pumiglia. "Focal Adhesion Kinase Controls Cellular Levels of p27/Kip1 and p21/Cip1 through Skp2-Dependent and -Independent Mechanisms". Molecular and Cellular Biology 26, n.º 11 (1 de junio de 2006): 4201–13. http://dx.doi.org/10.1128/mcb.01612-05.
Texto completoCheng, Qiong, Zhikun Ma, Yujie Shi, Amanda B. Parris, Lingfei Kong y Xiaohe Yang. "FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells". Cells 10, n.º 11 (4 de noviembre de 2021): 3008. http://dx.doi.org/10.3390/cells10113008.
Texto completoBonelli, Patrizia, Franca Maria Tuccillo, Antonella Borrelli, Antonietta Schiattarella y Franco Maria Buonaguro. "CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity". BioMed Research International 2014 (2014): 1–15. http://dx.doi.org/10.1155/2014/361020.
Texto completoWong, Gail A., Vincent Tang, Faten El-Sabeawy y Robert H. Weiss. "BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1". American Journal of Physiology-Endocrinology and Metabolism 284, n.º 5 (1 de mayo de 2003): E972—E979. http://dx.doi.org/10.1152/ajpendo.00385.2002.
Texto completoLiu, Wingsze, Coral Olazagasti, Chung-Shien Lee, Taylor Decina, Karalyn Pappas y Kit Cheng. "A single institution retrospective study of the effect of starting doses in patients with ER-positive metastatic breast cancer on CDK 4/6 inhibitors." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e13056-e13056. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e13056.
Texto completoPerecin, F., S. C. Méo, C. L. V. Leal y J. M. Garcia. "Oocyte activation and preimplantation development of bovine embryos obtained by specific inhibition of cyclin-dependent kinases". Arquivo Brasileiro de Medicina Veterinária e Zootecnia 59, n.º 2 (abril de 2007): 280–87. http://dx.doi.org/10.1590/s0102-09352007000200002.
Texto completoTakeuchi, S., HP Koeffler, DR Hinton, I. Miyoshi, S. Melmed y I. Shimon. "Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors". Journal of Endocrinology 157, n.º 2 (1 de mayo de 1998): 337–41. http://dx.doi.org/10.1677/joe.0.1570337.
Texto completoTakeuchi, S., CR Bartram, T. Seriu, CW Miller, A. Tobler, JW Janssen, A. Reiter, WD Ludwig, M. Zimmermann y J. Schwaller. "Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood". Blood 86, n.º 2 (15 de julio de 1995): 755–60. http://dx.doi.org/10.1182/blood.v86.2.755.bloodjournal862755.
Texto completoHoward, David, David James, Kate Murphy, Jezabel Garcia-Parra, Belen Pan-Castillo, Stuart Rex, Annemarie Moul et al. "Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer". Cancers 13, n.º 5 (6 de marzo de 2021): 1135. http://dx.doi.org/10.3390/cancers13051135.
Texto completoRoman-Gomez, Jose, Juan Antonio Castillejo, Antonio Jimenez, Maria Gracia Gonzalez, Fernanda Moreno, Maria del Carmen Rodriguez, Manuel Barrios, Juan Maldonado y Antonio Torres. "5′ CpG island hypermethylation is associated with transcriptional silencing of the p21CIP1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia". Blood 99, n.º 7 (1 de abril de 2002): 2291–96. http://dx.doi.org/10.1182/blood.v99.7.2291.
Texto completoSemiglazov, V. F., M. A. Dzhelialova, S. S. Yerechshenko, E. T. Munaeva, R. S. Pesotsky, A. I. Tseluyko, A. S. Emelyanov, R. V. Donskikh y P. V. Krivorotko. "Post-neoadjuvant treatment of breast cancer". Meditsinskiy sovet = Medical Council, n.º 9 (30 de julio de 2020): 232–41. http://dx.doi.org/10.21518/2079-701x-2020-9-232-241.
Texto completoMoreno-Lorenzana, Dafne, Sócrates Avilés-Vazquez, Miguel Angel Sandoval Esquivel, Antonio Alvarado-Moreno, Vianney Ortiz-Navarrete, Héctor Torres-Martínez, Manuel Ayala-Sánchez, Héctor Mayani y Antonieta Chavez-Gonzalez. "CDKIs p18INK4cand p57Kip2are involved in quiescence of CML leukemic stem cells after treatment with TKI". Cell Cycle 15, n.º 9 (17 de marzo de 2016): 1276–87. http://dx.doi.org/10.1080/15384101.2016.1160976.
Texto completoGuida, L., M. Annunziata, I. Passaro, C. Buonaiuto, R. Rullo, S. Tetè, F. Della Ragione y A. Oliva. "Acetylsalicylic Acid Inhibits Proliferation of Human Bone Marrow Stromal Cells and Matrix Mineralization". International Journal of Immunopathology and Pharmacology 21, n.º 4 (octubre de 2008): 921–28. http://dx.doi.org/10.1177/039463200802100416.
Texto completoChang, Mei-Yin, Den-En Shieh, Chung-Chi Chen, Ching-Sheng Yeh y Huei-Ping Dong. "Linalool Induces Cell Cycle Arrest and Apoptosis in Leukemia Cells and Cervical Cancer Cells through CDKIs". International Journal of Molecular Sciences 16, n.º 12 (26 de noviembre de 2015): 28169–79. http://dx.doi.org/10.3390/ijms161226089.
Texto completoCampbell, M. J., E. Elstner, S. Holden, M. Uskokovic y H. P. Koeffler. "Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin". Journal of Molecular Endocrinology 19, n.º 1 (agosto de 1997): 15–27. http://dx.doi.org/10.1677/jme.0.0190015.
Texto completoAmani, Jafar, Nassim Gorjizadeh, Simin Younesi, Mojtaba Najafi, Arash M. Ashrafi, Saeed Irian, Negar Gorjizadeh y Khalil Azizian. "Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer". DNA Repair 102 (junio de 2021): 103103. http://dx.doi.org/10.1016/j.dnarep.2021.103103.
Texto completoChen, Jun, Frank Hong y Perry D. Nisen. "Gene therapy for human brain tumors by ectopic overexpression of cell cycle cyclin-dependent kinase inhibitors (CDKIs) • 646". Pediatric Research 41 (abril de 1997): 110. http://dx.doi.org/10.1203/00006450-199704001-00666.
Texto completoRiera, María F., Mariana Regueira, María N. Galardo, Eliana H. Pellizzari, Silvina B. Meroni y Selva B. Cigorraga. "Signal transduction pathways in FSH regulation of rat Sertoli cell proliferation". American Journal of Physiology-Endocrinology and Metabolism 302, n.º 8 (15 de abril de 2012): E914—E923. http://dx.doi.org/10.1152/ajpendo.00477.2011.
Texto completoFreidkin, Ilya, Michal Herman, Ana Tobar, Avry Chagnac, Yaacov Ori, Asher Korzets y Uzi Gafter. "Effects of histone deacetylase inhibitors on rat mesangial cells". American Journal of Physiology-Renal Physiology 298, n.º 2 (febrero de 2010): F426—F434. http://dx.doi.org/10.1152/ajprenal.00107.2009.
Texto completoYang, Zhongfa, Karen Drumea, James Cormier, Junling Wang, Xuejun Zhu y Alan G. Rosmarin. "Gabp Transcription Factor Is Required for Self-Renew and Proliferation of Hematopoietic Stem and Progenitor Cells". Blood 118, n.º 21 (18 de noviembre de 2011): 1284. http://dx.doi.org/10.1182/blood.v118.21.1284.1284.
Texto completoYao, Kevin C., Tadashi Komata, Yasuko Kondo, Takao Kanzawa, Seiji Kondo y Isabelle M. Germano. "Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of cyclin-dependent kinase inhibitors, and autophagy". Journal of Neurosurgery 98, n.º 2 (febrero de 2003): 378–84. http://dx.doi.org/10.3171/jns.2003.98.2.0378.
Texto completoVelázquez, Carolina, Esin Orhan, Imene Tabet, Lise Fenou, Laura Boudarel, William Jacot, Claude Sardet y Charles Theillet. "Exploiting DNA Repair Defect in Triple Negative Breast Cancer Using CDK Inhibition Strategy". Medical Sciences Forum 3, n.º 1 (29 de enero de 2021): 13. http://dx.doi.org/10.3390/iecc2021-09212.
Texto completoFang, Jing, Lyndsey Bolanos, Juana Serrano-Lopez, Susanne Christie, Jose A. Cancelas y Daniel T. Starczynowski. "TRAF6 Is Essential for Maintaining Hematopoietic Stem Cell Homeostasis". Blood 128, n.º 22 (2 de diciembre de 2016): 568. http://dx.doi.org/10.1182/blood.v128.22.568.568.
Texto completoTrivellin, Giampaolo, Ricardo R. Correa, Maria Batsis, Fabio R. Faucz, Prashant Chittiboina, Ivana Bjelobaba, Darwin O. Larco et al. "Screening for GPR101 defects in pediatric pituitary corticotropinomas". Endocrine-Related Cancer 23, n.º 5 (mayo de 2016): 357–65. http://dx.doi.org/10.1530/erc-16-0091.
Texto completoBeksac, Meral, Ender Soydan, Selami Kocak Toprak, Merih Kizil, Gulsah Kaygusuz y Isinsu Kuzu. "Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma." Blood 106, n.º 11 (16 de noviembre de 2005): 5117. http://dx.doi.org/10.1182/blood.v106.11.5117.5117.
Texto completo